@article{Lane_J-2020_7575,
title = {Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis:a multinational network cohort study},
author = {Lane, J. and Weaver, J. and Kostka, K. and Duarte-Salles, T. and Abrahão, M. and Alghoul, H. and Alser, O. and Alshammari, T. and Areia, C. and Biedermann, P. and Banda, J. and Burn, E. and Casajust, P. and Fišter, K. and Hardin, J. and Hester, L. and Hripcsak, G. and Kaas-Hansen, B. and Khosla, S. and Kolovos, S. and Lynch, K. and Makadia, R. and Mehta, P. and Morales, D. and Morgan-Stewart, H. and Mosseveld, M. and Newby, D. and Nyberg, F. and Ostropolets, A. and Woong Park, R. and Prats-Uribe, A. and Rao, G. and Reich, C. and Rijnbeek, P. and Sena, A. and Shoaibi, A. and Spotnitz, M. and Vignesh, S. and Suchard, M. and Vizcaya, D. and Wen, H. and de Wilde, M. and Xie, J. and You, S. and Zhang, L. and Lovestone, S. and Ryan, P. and Prieto-Alhambra, D.},
month = {dec},
year = {2020},
abstract = {Objectives: Concern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.},
journal = {Rheumatology},
publisher = {Oxford University Press},
url = {https://doi.org/10.1093/rheumatology/keaa771},
}
